trial · primary record
ixazomib citrate
Refractory Plasma Cell Myeloma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2022-12-01 |
| Primary endpoint | Number of Patients With Dose-Limiting Toxicities (Phase I) |
| Registry ID | NCT02119468 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:48.531Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02119468
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.